2 news items
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
LEGN
11 Mar 24
; competition in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19 pandemic
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
LEGN
23 Feb 24
in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19 pandemic
- Prev
- 1
- Next